Results 101 to 110 of about 239,315 (295)
NEW CENTRAL STATION PRAGUE - OPERA
Diplomová práce se zabývá podzemní stanicí Praha-Opera v rámci zamýšleného komplexu železničních tunelů pod centrem Prahy. Práce rozpracovává zamýšlenou koncepci z hlediska zapojení tohoto rozsáhlého infrastrukturálního projektu do urbánní struktury ...
Zdeněk Völfl
core
Homo‐ and heterodinuclear group 4 metallocene complexes of the type [(Cp2M)2(μ‐Me)(μ‐C2R)] (M = Ti, Zr) are active catalysts for the polymerization of ethylene in the presence of aluminium‐free activators. The catalytically active species are proposed to have dinuclear character and depending on the type of activator, unique reactivity was observed ...
Hanan Al Hamwi +8 more
wiley +1 more source
Description of Weiner’s visit with the Council of Jewish religious communities in Czechoslovakia.Part of the Prague Jewish community collection, AR 377, folder ...
Weiner, Lewis
core
V rámci své diplomové práce zpracovávám návrh Koncertního sálu pro Prahu, v lokalitě Vltavská. Dlouho diskutované téma na kontroverzní parcele, s historií a potenciálem. Návrh sám přináší nový úhel pohledu, na budoucí město.
Julie Salavová
core
Organelle‐Resolved Tetrazine‐trans‐Cyclooctene Click Chemistry for Cargo Delivery and Release
Bioorthogonal click chemistry tools provide a means for specific intracellular conjugation of molecules. In this study, we used reactive tetrazine (Tz) and TCO moieties for labeling of organelles and organelle‐specific delivery and activation of doxorubicin prodrugs.
Oleh Durydivka +6 more
wiley +1 more source
C‐Terminal Tail Elongation Adds a New Dimension to the Tubulin Code
ABSTRACT Tubulin C‐terminal tails undergo diverse post‐translational modifications that regulate microtubule interactions with motors and severing enzymes. TTLL11, a member of the tubulin tyrosine ligase‐like (TTLL) family, uniquely catalyzes glutamate addition to the terminal α‐carboxyl group of both α‐ and β‐primary tubulin tails.
Jana Campbell, Cyril Barinka
wiley +1 more source
Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor +12 more
wiley +1 more source

